Prosecution Insights
Last updated: April 19, 2026
Application No. 18/566,449

PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFOXIMINE CONTAINING SUBSTITUENTS

Non-Final OA §102§103
Filed
Dec 01, 2023
Examiner
ROSENTHAL, ANDREW S
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Syngenta Crop Protection AG
OA Round
1 (Non-Final)
51%
Grant Probability
Moderate
1-2
OA Rounds
2y 11m
To Grant
93%
With Interview

Examiner Intelligence

Grants 51% of resolved cases
51%
Career Allow Rate
331 granted / 645 resolved
-8.7% vs TC avg
Strong +42% interview lift
Without
With
+41.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
49 currently pending
Career history
694
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
53.6%
+13.6% vs TC avg
§102
11.3%
-28.7% vs TC avg
§112
17.7%
-22.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 645 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The instant application is the national stage entry of PCT/EP2022/064778 filed 31 May 2022. Acknowledgement is made of the Applicant’s claim of foreign priority to application IN202111024601 filed 2 June 2021. Election/Restrictions Applicant’s election with traverse of Group I (Claims 1-16 and 20) in the reply filed on 26 December 2025 is acknowledged. Applicant’s election with traverse of Example P15 (below) as the species of formula I in the reply filed on 26 December 2025 is acknowledged. PNG media_image1.png 120 301 media_image1.png Greyscale Claims 2, 4-11, and 17-19 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 26 December 2025. The traversal is on the ground(s) that the ISA found the present claims to be both novel and inventive. This is not found persuasive because the Examiner has previously explained how the claimed groups lack unity of invention based on the disclosure of Edmunds et al. (WO 2020/084075). The requirement is still deemed proper and is therefore made FINAL. Status of the Claims Claims 1-20 are pending. Claims 2, 4-11, and 17-19 are withdrawn. Claims 1, 3, 12-16, and 20 are rejected. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 3, 12-15, and 20 are rejected under 35 U.S.C. 102a1 as being anticipated by Edmunds et al. (WO 2020/084075). Edmunds teaches the following structure P2 in a free form which anticipates the elected species of instant claims 1, 3, 12-15, and 20 (pg 68, lns 1-5). The structure of P2 is a racemic mixture and thus necessarily comprises both the R and the S configurations, by definition. Regarding instant claim 20, the claim comprises a product-by-process limitation. “If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process.” (See MPEP 2113 (I)). PNG media_image2.png 216 593 media_image2.png Greyscale Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim 1, 3, 12-16, and 20 are rejected under 35 U.S.C. 103 as being unpatentable over Edmunds et al. (WO 2020/084075). Edmunds teaches the following structure P2 which reads on the racemic mixture of the elected species of instant claims 1, 3, 12-15, and 20 (pg 68, lns 1-5). The structure of P2 is a racemic mixture and thus necessarily comprises both the R and the S configurations, by definition, however Edmunds teaches that an enantiomer thereof can be prepared (pg 2, lns 8-9). The compounds of formula (I) can be in free form or the form of salts (pg 40, lns 8-9). The composition of Edmunds can comprise a compound of formula (I) (structure P2) or an enantiomer thereof as well as an auxiliary or diluent (pg 24, lns 10-15), thus rendering obvious instant claims 1, 3, 12-16, and 20. Regarding instant claim 20, the claim comprises a product-by-process limitation. “If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process.” (See MPEP 2113 (I)). PNG media_image2.png 216 593 media_image2.png Greyscale Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANDREW S ROSENTHAL whose telephone number is (571)272-6276. The examiner can normally be reached M-F 8-5pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian Kwon can be reached at 571-272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANDREW S ROSENTHAL/ Primary Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Dec 01, 2023
Application Filed
Jan 15, 2026
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599605
URIC ACID LIPOSOMES
2y 5m to grant Granted Apr 14, 2026
Patent 12594335
PLATINUM-BASED DRUG-/PHOTOSENSITIZER-LOADED PROTEIN NANOPARTICLE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12594304
METHOD FOR TREATING LIVER CIRRHOSIS BY USING COMPOSITION COMPRISING MESENCHYMAL STEM CELL, EXTRACELLULAR VESICLE PRODUCED BY MESENCHYMAL STEM CELL, AND GROWTH FACTOR
2y 5m to grant Granted Apr 07, 2026
Patent 12582784
DRY POWDER INHALATION SYSTEM
2y 5m to grant Granted Mar 24, 2026
Patent 12576020
INCREASING THE STABILITY OF AGENTS FOR THE TREATMENT OF KERATINOUS MATERIAL
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
51%
Grant Probability
93%
With Interview (+41.5%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 645 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month